Head and Neck Squamous Cell Carcinoma - KOL Insight

PUBLISHED: March 12, 2024

PAGES:

DELIVERY TIME: 1-2 business days

Description

What underpins KOLs' views that novel strategies combining PD-1 therapies with bispecifics, ADCs and HPV-directed vaccines could disrupt first-line and later-line therapy in R/M HNSCC? How do experts assess the potential of Merck Group's inhibitor-of-apoptosis proteins antagonist xevinapant in the treatment of LA-HNSCC? KOLs critically assess the prospects of launched and pipeline therapies.

Companies Listed:

Roche
Pfizer
Merck & Co.
Bristol Myers Squibb
Astellas
Rakuten Medical
Kura Oncology
Exelixis
BioNTech

Merck Group
Coherus
Junshi Biosciences
ISA Pharmaceuticals
PDS Biotechnology
Adlai Nortye
CEL-SCI
Cue Biopharma
Bicara

Executive summary (9)

Current and future treatment algorithm (1)

Research objectives (3)

PD-1/L1 inhibitors (40)

Approved drugs (31)
- Keytruda (pembrolizumab; Merck & Co.) (9)
- Opdivo (nivolumab; Bristol Myers Squibb) (13)
- Loqtorzi (toripalimab; Coherus/Junshi) (9)
Pipeline drugs (9)
- Tecentriq (atezolizumab; Roche) (9)

Novel immunotherapies (25)

Pipeline drugs (25)
- HPV therapeutic vaccines (ISA Pharmaceuticals; PDS Biotechnology; BioNTech) (11)
- Multikine (leukocyte interleukin; CEL-SCI) (7)
- CUE-101 (Cue Biopharma) (7)

Targeted therapies (42)

Pipeline drugs (42)
- Xevinapant (Debio 1143; Merck Group) (9)
- ASP-1929 (cetuximab sarotalocan; Rakuten Medical) (10)
- AN2025 (buparlisib; Adlai Nortye) (7)
- Tipifarnib (Kura Oncology) (9)
- Antibody-drug conjugates (e.g. Padcev [enfortumab vedotin; Astellas/Pfizer]; Kadcyla [trastuzumab emtansine; Roche]) (7)